Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heterocyclic compound for treating Alzheimer disease and preparation method thereof

A technology of heterocyclic compounds and solvates, applied in the field of medicine, can solve the problems of serious adverse reactions of liver toxicity and few clinical problems, and achieve the effects of good acetylcholinesterase activity, inhibiting acetylcholinesterase activity and improving memory function.

Active Publication Date: 2017-09-08
佳木斯大学附属第一医院
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tacrine is rarely used clinically because of its hepatotoxicity and serious adverse reactions
Donepezil, rivastigmine, and galantamine are three widely used second-generation AChE inhibitors for the treatment of AD, all of which exhibit high acetylcholinesterase inhibitory activity and mild toxicity, but these AChE inhibitors only It can alleviate the symptoms of AD but cannot reverse its pathological process, that is, it cannot fundamentally cure AD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic compound for treating Alzheimer disease and preparation method thereof
  • Heterocyclic compound for treating Alzheimer disease and preparation method thereof
  • Heterocyclic compound for treating Alzheimer disease and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: 1-(4-((5-(2-hydroxyethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)phenyl)guanidine (compound 1)

[0054]

[0055] 5-(2-hydroxyethoxy)benzo[d]oxazol-2(3H)-one (3.9g), 1-(4-(bromomethyl)phenyl)guanidine (5.0g), carbonic acid A mixture of potassium (5.6g) in acetonitrile (400mL) was stirred and refluxed for 12h, the solvent was removed in vacuo, and the residue was eluted by gradient chromatography on a silica gel column. The mobile phase was petroleum ether / ethyl acetate 10:1 to 1:1, and the collected According to the corresponding components, 6.1 g of the title compound was obtained as a white solid, with a yield of 89.6% and a content of 99.1%.

[0056] ESI-MS: 343.13[M+H] +

[0057] Elemental analysis: theoretical value / measured value, C(59.64 / 59.54), H(5.30 / 5.38), N(16.37 / 16.48), O(18.69 / 18.71)

[0058] 1 H NMR (400MHz, CDCl 3 )δ8.99(s,1H),7.86(s,1H),7.34(s,1H),7.15(d,1H),6.91(d,2H),6.74(d,1H),6.64(s,2H ), 6.32(d,2H), 4.93(s,1H), 4.74(s,2H), 4.31(t,2...

Embodiment 2

[0059] Example 2: 1-(6-((5-(2-hydroxyethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)pyridin-3-yl) Guanidine (compound 2)

[0060]

[0061] 5-(2-hydroxyethoxy)benzo[d]oxazol-2(3H)-one (3.9g), 1-(6-(bromomethyl)pyridin-3-yl)guanidine (5.0g ), a mixture of potassium carbonate (5.6g) in acetonitrile (400mL) was stirred and refluxed for 12h, the solvent was removed in vacuo, and the residue was eluted by gradient chromatography on a silica gel column, and the mobile phase was petroleum ether / ethyl acetate 8:1 to 1: 1. Collect the corresponding components to obtain 5.9 g of the title compound as a white solid, with a yield of 85.4% and a content of 99.2%.

[0062] ESI-MS: 344.13[M+H] +

[0063] Elemental analysis: theoretical value / measured value, C(55.97 / 55.84), H(4.99 / 4.88), N(20.40 / 20.52), O(18.64 / 18.76)

[0064] 1 H NMR (400MHz, CDCl 3 )δ8.98(s,1H),7.86(s,1H),7.72(d,1H),7.56(d,1H),7.34(s,1H),7.26(d,1H),7.13(d,1H ), 6.74(d,1H), 6.64(s,2H), 4.93(s,1H), 4.54(s,2H), 4.31(t,2H...

Embodiment 3

[0065] Example 3: 1-(6-((5,6-bis(2-methoxyethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)pyridine -3-yl)guanidine (compound 3)

[0066]

[0067] 5,6-bis(2-methoxyethoxy)benzo[d]oxazol-2(3H)-one (5.7g), 1-(6-(bromomethyl)pyridin-3-yl ) The mixture of guanidine (5.0g), potassium carbonate (5.6g) in acetonitrile (400mL) was stirred and refluxed for 16h, the solvent was removed in vacuo, and the residue was eluted by silica gel column chromatography gradient, and the mobile phase was ether / ethyl acetate 5: From 1 to 1:1, the corresponding components were collected to obtain 7.0 g of the title compound as a light yellow solid, with a yield of 81.4% and a content of 98.9%.

[0068] ESI-MS: 432.18[M+H] +

[0069] Elemental analysis: theoretical value / measured value, C(55.68 / 55.75), H(5.84 / 5.88), N(16.23 / 16.14), O(22.25 / 22.23)

[0070] 1 H NMR (400MHz, CDCl 3 )δ8.98(s,1H),7.86(s,1H),7.73(d,1H),7.54(d,1H),7.22(s,1H),7.13(d,1H),6.74(s,1H ), 6.64(s,2H), 4.50(s,2H), 4.31(t,4H), 3.7...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a heterocyclic compound for treating Alzheimer disease and a preparation method thereof. The heterocyclic compound has a good effect of inhibiting the activity of acetyl cholinesterase; as proved by a behavioral experiment research of a senescence-accelerated mouse (SAM-P / 8), the heterocyclic compound can effectively improve the memory function of the SAM-P / 8 mouse, so that the heterocyclic compound can be used for treating cognitive dysfunction and / or neural degeneration dementia with abnormal protein aggregation, particularly the Alzheimer disease.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a benzoxazolone heterocyclic compound for treating Alzheimer's disease, and also relates to a preparation method of the heterocyclic compound. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease that occurs in old age and is characterized by dementia. Its main clinical manifestations are progressive cognitive dysfunction and memory decline, personality and behavior changes, decreased judgment, social impairment, loss of self-care ability, and eventually death, which seriously endangers the health and quality of life of the elderly. With the aging of the population, Alzheimer's disease, mainly AD, has become the third major disease that threatens the lives of the elderly after cardiovascular and cerebrovascular diseases and malignant tumors. AD not only seriously endangers the health of the elderly, but also brings a heavy mental burden to the f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D263/58C07D413/06A61K31/421A61K31/4439A61K31/5377A61P25/28
CPCC07D263/58C07D413/06
Inventor 李欣罗海龙宋广福于佳楠程鹏飞盛宝英王丽华
Owner 佳木斯大学附属第一医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com